Meet Rebecca: Building the Data Foundations Behind AI-Powered Clinical Trials
Meet Sammy: Clinical Project Manager at Qureight
Meet Jeremy: From Musician to Front-End Engineer at Qureight
Qureight appoints Rebecca Simmons as Chief Operating Officer
Qureight appoints Dr Steven Bishop as Chief Medical Officer
Comparison of the Baseline Clinical and HRCT Characteristics of Insilico’s ISM001_055 Phase 2a Trial Cohort in China with Real-World IPF Datasets
2025 ERS Abstract
PMG1015 Demonstrates a Well-Tolerated Safety Profile and Favorable FVC Changes after 12 Weeks of Treatment in IPF Patients
2025 ERS Abstract
Deep Learning-based Fibrosis and Ground Glass Opacification Quantification with Proteomic Biomarkers for Outcome Prediction in Idiopathic Pulmonary Fibrosis.
2025 ERS Abstract
Longitudinal Changes in Quantitative Imaging Biomarkers are Associated with Increased Risk of Mortality in Connective Tissue Disease-Related Interstitial Lung Disease
2025 ERS Abstract
Deep Learning-Based Airway and Vessel Volume are Associated with Increased Risk of Mortality in Connective Tissue Disease-Related Interstitial Lung Disease.
2025 ERS Abstract
Deep Learning-based Image Quantification of CTPA to Phenotype Pulmonary Arterial Hypertension
2025 ERS Abstract
Deep Learning Analysis of Serial CT Scans Correlates with Changes in how Patients Feel, Function and Survive in Fibrotic Interstitial Lung Disease
2025 ERS Abstract
The Role of Quantitative CT in the Prognostication and Monitoring of Systemic Autoimmune Rheumatic Disease Related Interstitial Lung Disease
2025 BTS Abstract
Qureight Vascul8 model for pulmonary vascular disorders validated in peer-reviewed study, offering potential to improve treatment options and patient outcomes following surgery
Pulmonary Blood Volumes on CT Predict Residual Pulmonary Hypertension Post-Pulmonary Endarterectomy
Combined Deep Learning Algorithms Demonstrate That Both Computed Tomography Phenotype and Anatomical Biomarkers Are Predictive of Prognosis and Progression in Idiopathic Pulmonary Fibrosis
ATS Journals
Qureight has major presence at 2025 ERS Congress to highlight how advanced imaging biomarkers and AI are transforming interstitial lung disease research and drug development
